When will the THAM patents expire, and when will THAM go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	THAM	tromethamine	SOLUTION;INJECTION	013025-002	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Hospira	THAM-E	potassium chloride; sodium chloride; tromethamine	INJECTABLE;INJECTION	013025-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 20, 2026

THAM (Tris(hydroxymethyl)aminomethane) drug investment fundamentals: market use, regulatory posture, and IP durability

THAM (tris(hydroxymethyl)aminomethane) is a widely used buffering agent and alkalinizing therapeutic in acute-care settings. As an active ingredient, it is heavily genericized and typically sold as an injectable solution for acid-base management, limiting patent-driven exclusivity and shifting investment focus toward manufacturing scale, supply continuity, hospital contracting, and distribution execution rather than long-dated compound exclusivity.

What is THAM and how is it used clinically?

THAM (chemical name: tris(hydroxymethyl)aminomethane) is used to manage acid-base disorders, most commonly as an alkalinizing agent. Its clinical footprint is centered on inpatient, emergency, and critical care use where rapid correction of acidemia is required.

What acid-base indications drive THAM demand?

Key real-world demand drivers include:

Metabolic acidosis where alkalinization is selected over, or adjunct to, bicarbonate therapy
Prevention and management strategies in settings where urine alkalinization is clinically relevant (practice patterns vary by jurisdiction and protocol)
Situations involving drug-related acid burdens where clinicians select buffering strategies

What formulations are sold?

THAM is marketed primarily as an injectable solution (hospital supply model). That delivery format typically reduces product differentiation and increases the importance of:

Sterility assurance and batch release performance
Stability during distribution
Cost competitiveness against other alkalinizing/buffering products

What patents protect THAM and how strong is the IP estate?

Is THAM protected by long-term compound patents?

THAM’s underlying molecule is old and widely available. In practice, investment returns for THAM are rarely driven by new, high-value active ingredient patents. The asset class behaves like a commodity chemical with value tied to finished-dose manufacturing know-how, regulatory filings, and access to hospital distribution channels.

What types of patents could still matter?

Even when molecule exclusivity is minimal, investors typically underwrite residual IP in:

Specific finished-dose compositions (concentration, excipient systems)
Manufacturing processes (sterile fill-finish processes, impurity specifications, stability-enhancing methods)
Device-less product presentation differences (containers, labeling, or packaging strategies) that can create practical barriers to substitution
Method-of-use claims tied to defined patient subgroups, dosing regimens, or monitoring algorithms (these are less common for old buffer agents, but can exist at the product level)

What is the Orange Book status of THAM products?

THAM is generally supplied as an injectable buffering agent under multiple marketing authorizations. Orange Book status, when present, is usually limited to application-specific patents attached to a particular listed drug (formulation, process, or method-of-use) rather than platform compound patents.

Because THAM’s portfolio is typically generic and multiple manufacturers participate, the Orange Book “exclusivity story” is often short-lived and fragmented across product listings. That structure increases the probability that:

No single manufacturer holds meaningful long-term exclusivity on the ingredient
Competitive entry can occur at different times across strengths and label variants

When does THAM lose exclusivity and what generic entry risks exist?

For THAM as a chemical entity, the dominant generic entry risk is not a single Paragraph IV event. It is the low barrier to manufacturing a finished sterile solution once regulatory pathways and quality systems are in place.

What drives generic substitution in THAM?

Hospital buyers tend to substitute based on:

Price and contract terms
Supply reliability
Formulary status and purchasing group agreements
Clinical protocol compatibility (dose equivalence, infusion compatibility, and nursing workflow)

What is the practical exclusivity window?

For most THAM products, exclusivity tends to be measured in:

The life of the specific NDA/ANDA product listing and any attached patents
Market-specific tender cycles and contracting lock-ins
Any product-level patents that may be harder to design around due to formulation or process specifics

How does THAM compare with alternative alkalinizing therapies?

Bicarbonate as the main competitive benchmark

The main clinical comparator in acidemia management is sodium bicarbonate, along with other alkalinizing buffering strategies used under local protocols.

Investment relevance:

If protocols favor bicarbonate routinely, THAM’s addressable market narrows to protocol-driven niches and specific clinician preferences.
If THAM addresses constraints (tolerability, specific metabolic patterns, or monitoring practicality), the market can persist in acute-care bundles even as generic pressures remain intense.

Other buffering or correction agents

Other agents may compete based on:

Institutional guideline selection
Compatibility with co-administered therapies
Nursing and pharmacy handling constraints

Which companies are key THAM suppliers and what is the competitive landscape?

THAM supply is usually characterized by multiple generic manufacturers with overlapping finished-dose presentations. In such markets, competitive advantage typically comes from operational execution rather than IP.

Investment focus areas:

Manufacturing capacity and sterile fill-finish throughput
Quality track record and inspection outcomes
Ability to secure recurring hospital contracts
Regulatory and supply chain resilience during shortages

What FDA pathways apply to THAM products?

THAM products entering the US market generally use abbreviated pathways, reflecting that the ingredient is well characterized. The standard investment conclusion for this class is that regulatory timelines are not the main driver of value unless a specific product listing is tied to scarce manufacturing capability.

What matters more than pathway selection?

For sterile injectables like THAM, investor underwriting is dominated by:

Chemistry, manufacturing, and controls readiness
Sterile processing validation strength
Batch release predictability and impurity control
Stability data supporting shelf life in labeled storage conditions

What manufacturing and IP barriers block competitors for THAM?

Even with limited molecule-level IP, barriers can exist in practice.

Sterile manufacturing constraints that matter

Validated terminal sterilization or aseptic processing capability
Container closure system performance and extractables/leachables controls
Consistent pH and buffering capacity across lots
Contamination prevention during fill-finish

Quality and supply risk as a moat

In hospital supply markets, a strong quality record can function as a practical moat because buyers penalize unreliable sources. Investors typically underwrite:

DMF readiness and site approvals
Inspection history
Capacity to maintain contract volume during demand spikes

What patent litigation affects THAM and how should investors diligence risk?

For old, widely available active ingredients like THAM, litigation tends to be:

Product-level rather than compound-level
Focused on specific process or formulation patents (when present)
Intermittent rather than continuous, unless a particular branded or semi-branded product remains under active protection

In diligence, the decision gate is whether any asserted patents could delay generic approvals for a specific strength or presentation. Most of the time for THAM-style assets, that gate closes quickly, shifting the risk profile from legal to execution.

What licensing deals and commercial terms are typical for THAM?

THAM licensing is often about:

Acquiring manufacturing rights and regulatory dossiers for specific presentations
Securing supply agreements that guarantee volume and margin
Using portfolio licensing to consolidate sterile injectable manufacturing footprint

Investment-grade structures tend to include:

Batch-based transfer pricing
Minimum supply commitments with quality SLAs
Explicit regulatory responsibility allocation (CMC ownership, supplements, and variations)

What is the revenue exposure model for a THAM investment?

Revenue is usually tied to:

Hospital and group purchasing organization contracting
Seasonal or episodic spikes driven by clinical demand
Tender cycles and formulary decisions
Substitution rates against sodium bicarbonate and other alkalinizing strategies

How do margins typically behave?

Commodity-like sterile injectables often show:

Price pressure as multiple suppliers compete
Margin compression during periods of new entry or supply normalization
Margin resilience only when a supplier has supply scarcity, quality reputation, or contract lock-ins

How strong is the patent estate for THAM versus newer specialty assets?

Compared with specialty injectables with long-lived method-of-use, device-linked, or biologic exclusivities, THAM generally has:

Short exclusivity horizons tied to specific product listings
Lower probability of large incremental R&D moats
Higher probability that value comes from operational scale and regulatory execution

The investment implication is to model the downside as:

Rapid price erosion once competition expands
Contract renegotiation and rebid cycles
Substitution toward the most cost-effective alkalinizing approach

Key takeaways for THAM investment screening

THAM value creation is primarily commercial and operational, not compound-IP driven.
Exclusivity, when it exists, is usually product-specific and short-lived relative to specialty drug timelines.
Generic entry risk is structurally high, so underwriting must focus on supply reliability, sterile manufacturing performance, and hospital contracting.
The competitive set is less about direct THAM-to-THAM differentiation and more about alkalinizing alternatives, mainly sodium bicarbonate, under institutional protocols.

FAQs

1) Are THAM products protected by method-of-use patents?
Any protection is typically limited to product-level patents attached to particular indications, dosing, or monitoring claims tied to specific labels, rather than broad molecule exclusivity.

2) What is the biggest risk to revenue for THAM suppliers?
Price erosion and loss of hospital tender position due to multi-source competition and substitution toward lower-cost alkalinizing regimens.

3) What differentiates THAM manufacturers when patent coverage is limited?
Manufacturing capacity for sterile fill-finish, batch consistency, inspection outcomes, and ability to maintain contract-volume supply.

4) How does supply disruption affect THAM margins?
Supply constraints can temporarily widen margins and support contract premiums, but those benefits often normalize when additional supply clears the market.

5) What diligence items matter most for a THAM investment?
Sterile CMC readiness, regulatory standing for each product strength/presentation, historic batch release performance, and signed purchasing agreements that specify volume, pricing, and quality SLAs.

References

U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
U.S. Food and Drug Administration. Drug Approval and Databases. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases

THAM Drug Patent Profile

Which patents cover Tham, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for THAM

US Patents and Regulatory Information for THAM